Sharing Information With US FDA Advisory Committee Can Invalidate Patent, Jazz Finds
Executive Summary
Federal Circuit rules that material about Xyrem's REMS distribution system provided for advisory committee review constitutes prior art.
You may also be interested in...
REMS Lawsuit Possible After US FDA Approves Generic Xyrem
FDA waives requirement that Roxane's generic use same REMS as the brand; Jazz ‘intends to evaluate all potential challenges.’ Launch of generic still depends on patent litigation.
Xyrem REMS Grudgingly Approved; FDA Worries About Blocked Generics
FDA approves a Risk Evaluation & Mitigation Strategy for Jazz Pharmaceutical’s Xyrem under protest; the agency says the single-pharmacy distribution plan for the narcolepsy treatment has the potential to block generic competitors from the market. FDA and Jazz had been working for seven years to agree to a REMS that confirms to the requirements under the FDA Amendments Act of 2007.
Xyrem Risk Management Plan Should Limit Drug's Use To Cataplexy - Cmte.
Orphan Medical's Xyrem risk management program should limit physician use of the gamma hydroxy butyrate product to treatment of cataplexy, FDA's Peripheral & Central Nervous System Drugs Advisory Committee said at its June 6 meeting.